Disposition of 24500 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 3.76 subject to Rule 16b-3
| APLS Stock | USD 35.42 1.49 4.39% |
Slightly above 54% of Apellis Pharmaceuticals' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Apellis Pharmaceuticals suggests that some traders are interested. Apellis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apellis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Apellis |
Filed transaction by Apellis Pharmaceuticals Officer: Chief Scientific Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Apellis Pharmaceuticals Fundamental Analysis
We analyze Apellis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Apellis Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Apellis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Apellis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Apellis Pharmaceuticals Related Equities
| ABOS | Acumen Pharmaceuticals | 3.52 | ||||
| INZY | Inozyme Pharma | 2.95 | ||||
| IMVT | Immunovant | 2.09 | ||||
| BPMC | Blueprint Medicines | 1.29 | ||||
| MREO | Mereo BioPharma | 0.55 | ||||
| AMLX | Amylyx Pharmaceuticals | 0.18 | ||||
| AKRO | Akero Therapeutics | 0.28 | ||||
| DAWN | Day One | 0.65 | ||||
| TERN | Terns Pharmaceuticals | 1.44 | ||||
| MDGL | Madrigal Pharmaceuticals | 2.94 | ||||
| XFOR | X4 Pharmaceuticals | 5.13 |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.